A significantly large percentage of new chemical entities (NCEs) are poorly soluble, and the industry is always on the lookout for new excipients to adapt in drug development technologies for poorly soluble compounds.
Amorphous solid dispersions (ASD) have been well recognized for improving the solubility of crystalline drugs. Among many technologies for ASD, hot melt extrusion (HME) technology is widely used across the industry for increasing solubility and bioavailability of NCEs. The excipients’ manufacturers are working together with drug manufactures to expedite the development process by introducing the innovative polymers for such technology.
This presentation will focus on physico-chemical characteristics of polymers suited for HME, with case studies showing the improvement of bioavailability by ASD.
Dr. Shaukat Ali has over 20 years of experience in the pharmaceutical industries including 10 years at BASF, where he is supporting the solubilization platform. Dr. Ali’s areas of expertise include drug solubilization, liposome drug delivery, controlled release and film development technologies.
He serves the USP panel of experts for General Chapters-Physical Analysis. He is a member of the editorial boards of American Pharmaceutical reviews, Contract Pharma, Drug Development & Delivery, Biopharma Asia (UK), International Journal of Pharmaceutical Investigation. He has authored over 25 scientific articles and is inventor/co-inventor in 14 US patents.
He received his Ph.D. in Chemistry from the City University of New York and pursued his postdoctoral interest at the University of Minnesota and Cornell University. He is an adjunct faculty at the College of Pharmacy, University of South Florida, Tampa, FL.